rome75, you're right. roche folks and/or dr. garnick can afford some strategic mistakes when bringing a new platform forward... and they have made a few. Nobody is perfect on new ground. I don't mind terribly the errors made along the way, most before Roche/DNA were fully aboard. For instance it was a matter of survival to start trials with Bavi + chemo rather than Bavi+ irradiation. That was a time when unknown forces were REALLY trying to starve PPHM, and the last straw to grasp before drowning was Bavi+chemo trials in India. We did not have the wherewithal to run a trial in this country then. But that was then. See? Things HAVE improved. We are here because PPHM stockholders have carried the load for this cheapo R&D for enormously well-moneyed big pharma people. We've seen a 20%+ drop in stock value compared to broader markets in the past few months, and mostly dilution. We can reasonably expect a near-spectacular multiple on our investment if Bavi flies. Remember, they will take our shares for whatever they can get them for.
News 
Market Data 
Discover 
AI
